Table 1 Literature overview of breast MECs
No | Authors | Year of publication | Age | Tumor dimension (cm) | Grading | Lymph node metastasis | Distant Metastasis | Type of surgery | Adjuvant therapy | Follow-up (months) | ER−PR status | HER2 status | Molecular analysis (MAML2translocation) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Patchefsky et al. [10] | 1979 | 70 | 5 | LG | NA | No | Q | NA | 10 alive | NA | NA | NA |
2 | 66 | 1.3 | LG | No | No | RM | NA | 94 DOR | NA | NA | NA | ||
3 | Kovi et al. [11] | 1981 | 46 | 11 | HG | Yes | NA | MRM | NA | NA | NA | NA | NA |
4 | Fisher et al. [12] | 1983 | 60 | 4 | LG | NA | No | SM | NA | 48 alive | NA | NA | NA |
5 | 49 | 3.7 | LG | No | No | RM | NA | 108 alive | NA | NA | NA | ||
6 | 57 | 2.5 | LG | No | No | MRM | NA | 120 alive | NA | NA | NA | ||
7 | 71 | 2 | LG | No | No | MRM | NA | 48 alive | NA | NA | NA | ||
8 | 65 | 2 | LG | NA | No | L | NA | 60 alive | NA | NA | NA | ||
9 | Ratanarapee et al. [13] | 1983 | 27 | NA | HG | Yes | Yes | NA | NA | 14 DOD | NA | NA | NA |
10b | Leong and Williams [14] | 1985 | 57 | 3.5 | HC | No | Yes | SM | No | 7 DOD | NA | NA | NA |
11 | Hastrup and Sehested [15] | 1985 | 59 | 1 | HG | No | Yes | RM | RT+CT+HT | 25 DOD | −− | NA | NA |
12b | Hanna and Kahn [16] | 1985 | 31 | NA | NA | Yes | No | MRM | CT | 14 alive | +− | NA | NA |
13b | 51 | 2 | NA | No | No | MRM | No | 8 alive | +− | NA | NA | ||
14b | Pettinato et al. [17] | 1989 | 72 | 7 | HG | Yes | Yes | MRM | CT | 10 DOD | NA | NA | NA |
15b | Luchtrath and Moll [18] | 1989 | 60 | 5 | HG | Yes | Yes | RM | NA | 30 DOD | NA | NA | NA |
16 | Chang et al. [19] | 1998 | 54 | 4.5 | HG | No | No | MRM | CT | 48 alive | NA | NA | NA |
17 | Markopoulos et al. [20] | 1998 | 40 | 2 | HG | No | No | L+ALND | NA | 60 alive | NA | NA | NA |
18 | Berry et al. [21] | 1998 | 51 | 3.5 | HG | No | no | MRM | NA | NA | NA | NA | NA |
19 | Tjalma et al. [22] | 2002 | 58 | 3.5 | HG on LG | Yes | Yes | RM | NA | 156 alive | NA | NA | NA |
20 | Terzi et al. [23] | 2004 | 79 | 8 | HG | Yes | No | MRM | NA | NA | NA | NA | NA |
21 | Di Tommaso et al. [24] | 2004 | 36 | 0.6 | HG | NA | No | Q+ALND | NA | 18 alive | NA | NA | NA |
22 | 55 | 1.1 | IG | Na | No | Q+ALND | NA | 3 alive | NA | NA | NA | ||
23 | 54 | 1.5 | LG | NA | No | Q+ALND | NA | 13 alive | NA | NA | NA | ||
24 | 29 | 0.8 | LG | NA | No | L | NA | 90 alive | NA | NA | NA | ||
25 | 80 | 0.5 | LG | NA | No | L | NA | 5 alive | NA | NA | NA | ||
26 | Gomez−Aracil et al. [25] | 2006 | 69 | 6 | HG | Yes | No | MRM | CT | 54 alive | +− | NA | NA |
27 | Horii et al. [26] | 2006 | 54 | 2.5 | LG | No | No | MRM | HT | 36 alive | +− | − | NA |
28b | Hornychova et al. [27] | 2007 | 30 | 8 | LG | No | No | MRM | RT+CT | 60 alive | −− | − | NA |
29 | 63 | 1.8 | HG | No | No | MRM | RT+CT | 18 alive | −− | − | NA | ||
30b | Camelo-Piragua et al. [8] | 2009 | 49 | > 5, multiple microinvasive foci with extensive in situ | IG | Yes | No | MRM | CT | 8 alive | −− | − | + (del.11q21) |
31b | Basbug et al. [28] | 2011 | 69 | 10 | HG | No | No | MRM | RT+CT | 12 alive | −− | − | NA |
32 | Turk et al. [29] | 2013 | 40 | 5.5 | NA | Yes | No | MRM | CT | 5 alive | −− | − | NA |
33b | Palermo et al. [30] | 2013 | 80 | 4 | HG | No | No | NA | NA | NA | −− | NA | NA |
34 | Fujino et al. [31] | 2016 | 71 | 1.7 | IG | No | No | SM | NA | NA | −− | − | − (RT−PCR) |
35 | Cheng et al. [32] | 2017 | 61 | 3 | LG | No | No | SM | No | 4 alive | ++ | − | NA |
36 | 66 | 1.3 | LG | No | No | SM | No | 9 alive | +− | − | NA | ||
37 | 49 | 1.5 | LG | No | No | MRM | No | 41 alive | −− | − | NA | ||
38 | 39 | 1.5 | LG | Yes | No | MRM | No | 156 alive | ++ | − | NA | ||
39 | Sherwell-Cabello et al. [33] | 2017 | 86 | 6 | LG | No | No | MRM | No | 3 alive | −− | − | NA |
40b | Burghel et al. [34]a | 2018 | 73 | < 2 | LG | No | No | L | No | 50 alive | NA | NA | NA |
41 | GR Bean et al. [6] | 2018 | 49 | 5 | IG | Yes | No | MRM | CT | 12 alive | −− | − | + (FISH, RT−PCR) |
42 | 53 | 1.6 | LG | No | No | L | RT | 16 alive | −− | − | + (FISH, NGS, RT−PCR) | ||
43 | Mingfei Yan et al. [5]ª | 2019 | 60 | 1.9 | LG | NA | No | L | NA | 60 alive | −− | − | + (FISH) |
44 | Ru-Pei Ye et al. [35] | 2020 | 42 | 2.6 | LG | NA | No | MRM | CT | 12 alive | −− | − | NA |
45 | Fresia Pareja et al. [7]a | 2020 | NA | NA | LG | NA | NA | NA | NA | NA | −− | − | + (FISH, RNA sequencing RT−PCR) |
46 | Linda Metaxa et al. [36] | 2020 | 63 | 2.1 | LG | No | No | L | No | 36 alive | + NA | NA | NA |
47 | Black et al. [37] | 2023 | 65 | 1.3 | LG | No | No | L | RT | 30 alive | +− | − | + (FISH, RT−PCR, NGS)c |
48 | He et al. [38] | 2023 | 39 | 1.2 | LG | No | No | NA | NA | 24 | −− | − | + (FISH) |
49 | 37 | 1.2 | LG | No | No | NA | NA | 30 | −− | − | + (FISH) | ||
50 | 40 | 1.5 | IG | No | No | NA | NA | 12 | −− | − | + (FISH) | ||
51−63b, d | Venetis et al. [39] | 2023 | 41–75 (n = 13) | ≤ 2/(n = 8) 2.1–5/(n = 2) > 5/(n = 1) NA/(n = 3) | LG (n = 10) HG (n = 3) | No (n = 11) Yes (n = 1) NA (n = 1) | No (n = 10) Yes (n = 2) NA (n = 1) | NA (n = 13) | NA (n = 13) | NA (n = 13) | +(2/13)/−(13/13) | −(13/13) | −(10/10); (FISH) 8/13 (NGS) |
64 | Present case | 2023 | 58 | 2 | HG | No | No | SM | CT+TT | 61 alive | +− | + | − (FISH) |